Daily Pharma News - 29 October 2026

Welcome to PharmacoLearn's daily pharma news for 29 October 2026. Today's round-up brings together seven important stories for pharmacy students in India and abroad, covering cancer medicine pricing, tobacco control on campuses, eye-disease research from South India, a landmark stroke drug approval in China, drug safety action in Russia, a new generic approval in the United States, and head-to-head diabetes trial results. Read on for what each story means, and why it matters for your pharmacy education.

NPPA Revises MRPs for 543 Anti-Cancer Medicine Brands in India, Effective 9 November 2026

India's National Pharmaceutical Pricing Authority (NPPA) has published revised maximum retail prices (MRPs) for 543 anti-cancer medicine brands, effective from 9 November 2026. The revision follows the capping of trade margins on 137 non-scheduled drugs, a step aimed at making cancer treatment more affordable for patients across India. One striking example reported is anastrozole, a breast cancer medicine, whose price falls from Rs 695.76 to Rs 73.

For pharmacy students, this story is a live lesson in pharmaceutical pricing regulation in India. It connects directly to the Drug Price Control Order (DPCO), the difference between scheduled and non-scheduled formulations, and the role of the NPPA in balancing patient access with industry sustainability. When you dispense or counsel in future practice, understanding how MRPs are fixed, revised and enforced will help you explain price changes to patients and spot pricing irregularities in the supply chain.

India Launches Tobacco-Free Youth Campaign 4.0 for Colleges and Universities

India has launched the Tobacco-Free Youth Campaign (TFYC) 4.0 on 28 October 2026, a 60-day nationwide campaign that shifts its focus to colleges and universities. The campaign promotes tobacco-free campuses, stronger enforcement of the Cigarettes and Other Tobacco Products Act (COTPA), and student-led cessation support, placing young people at the centre of tobacco control efforts.

Pharmacy students have a special role in this story. Tobacco use is a major preventable cause of cancer, heart disease and lung disease, and pharmacists are often the most accessible health professionals for people trying to quit. Understanding COTPA, nicotine dependence, and the basics of cessation support will prepare you to take part in campus awareness drives and to guide patients towards appropriate, evidence-based help in your professional life.

Bharat Biotech Unit Nucelion and Pandorum Partner on Eye-Disease Therapies in South India

Hyderabad-based Nucelion Therapeutics, a Bharat Biotech unit, has partnered with Bengaluru-based Pandorum Technologies to advance two ophthalmology projects backed by the PRIP scheme. The collaboration targets advanced keratopathy, a serious corneal condition, and wet age-related macular degeneration (wet AMD), a leading cause of vision loss in older adults.

This partnership is a strong example of South India's growing strength in biotechnology and regenerative medicine. For students, it links classroom topics such as ocular drug delivery, corneal biology, retinal pharmacology and biologics development to real research happening in Hyderabad and Bengaluru. It also shows how government-backed programmes such as PRIP can support Indian companies in developing advanced therapies for unmet medical needs.

China Approves Bayer's Asundexian (Sunharbo), the World's First Factor XIa Inhibitor

China's National Medical Products Administration (NMPA) has approved Bayer's asundexian, marketed as Sunharbo (50 mg), to reduce the risk of stroke after a non-cardioembolic stroke or a high-risk transient ischaemic attack (TIA). The approval, granted after priority review, is based on the Phase III OCEANIC-STROKE study, and makes asundexian the first Factor XIa inhibitor approved anywhere in the world.

Factor XIa inhibition is an important new chapter in anticoagulant pharmacology. Unlike older anticoagulants that target Factor Xa or thrombin, Factor XIa inhibitors aim to prevent clot formation while potentially lowering bleeding risk, a balance that has long challenged stroke prevention. Pharmacy students should note the indication carefully: this approval is for secondary stroke prevention after non-cardioembolic stroke or high-risk TIA, not for all stroke types, and the drug's place in treatment guidelines will evolve as more evidence emerges.

Russia Updates Drug Safety Materials and Withdraws Two Medicine Consignments

Russia's drug regulator, Roszdravnadzor, issued letters on 26 October 2026 updating risk-minimisation materials for Xelticin and Eculeris, and withdrawing consignments of Citramon P and ASK-cardio over quality and labelling failures. Risk-minimisation materials are the safety communications, guides and warnings that help healthcare professionals and patients use a medicine safely, and updating them is a routine but vital part of pharmacovigilance.

This story is a useful reminder that drug safety does not end at approval. Quality failures, labelling errors and new safety information can all trigger regulatory action, recalls or withdrawals, and pharmacists are on the front line of spotting affected batches and advising patients. For students studying pharmacovigilance and quality assurance, it shows how regulators monitor medicines throughout their lifecycle and act to protect public health.

US FDA Approves Alembic's Generic Valganciclovir Oral Solution

The United States Food and Drug Administration (FDA) has granted final approval to Alembic Pharmaceuticals for its generic valganciclovir oral solution (50 mg/mL), the generic version of Valcyte. The approval covers treatment of cytomegalovirus (CMV) retinitis in patients with AIDS, and prevention of CMV disease in transplant patients.

Valganciclovir is an antiviral prodrug that is converted in the body to ganciclovir, and it remains a key medicine in transplant medicine and HIV care. For Indian pharmacy students, this approval highlights the strength of India's generic industry in regulated markets such as the United States, and the importance of bioequivalence, Abbreviated New Drug Application (ANDA) filings, and quality standards in bringing affordable generics to patients worldwide. The oral solution formulation is also clinically relevant, as liquid formulations help patients who cannot swallow tablets.

Retatrutide Beats Ozempic 2 mg on Blood Sugar and Weight in Phase III TRANSCEND-T2D-2 Trial

Eli Lilly's investigational medicine retatrutide has outperformed Ozempic (semaglutide) 2 mg in the Phase III TRANSCEND-T2D-2 trial in type 2 diabetes. At 80 weeks, retatrutide reduced HbA1c by 2.2% compared with 1.8% for Ozempic, and cut body weight by up to 20.9% compared with 9.4% for Ozempic. It is important to note that retatrutide remains investigational and is not yet approved for clinical use.

These results matter for diabetes pharmacology because they show how the next generation of incretin-based therapies is pushing beyond current standards for both glycaemic control and weight loss. Pharmacy students should read head-to-head trial results critically, comparing not only efficacy numbers but also trial duration, patient population, safety profile and whether a drug is approved or still under investigation. As obesity and type 2 diabetes continue to rise in India, understanding this evolving class will be essential for future practice.

Conclusion

Today's news ties together the core themes of modern pharmacy: access, safety, innovation and prevention. From NPPA's cancer medicine price cuts and the tobacco-free campus campaign in India, to new therapies for the eye, stroke and diabetes, and vigilant safety action on quality, each story shows pharmacists working at the intersection of regulation, research and patient care. For pharmacy students, the lesson is clear: stay updated on approvals and pricing, understand the pharmacology behind the headlines, and always check whether a promising trial result means an approved medicine or one still on its way. Keep learning with PharmacoLearn, and share today's news with your classmates.

References

← All daily news